stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Return on equity
CRISPR Therapeutics AG's return on equity over the twelve months to 30 September 2026 was −25.6%, up 4.6 percentage points from fiscal 2025 (−30.2%). Over the past ten years it has ranged from −56.9% (fiscal 2018) to 141.3% (fiscal 2015); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of −52.0% and in line with the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −30.2% | (10.98) |
| FY2024 | −19.2% | (11.03) |
| FY2023 | −8.17% | 22.25 |
| FY2022 | −30.4% | (49.01) |
| FY2021 | 18.6% | 45.39 |
| FY2020 | −26.8% | (36.84) |
| FY2019 | 10.0% | 66.93 |
| FY2018 | −56.9% | (24.39) |
| FY2017 | −32.5% | (9.75) |
| FY2016 | −22.8% | (164.05) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 92.2% |
| MANE Veradermics Incorporated compare | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −8.08% |
| DNTH Dianthus Therapeutics, Inc. compare | −22.6% |
| CRSP CRISPR Therapeutics AG | −25.6% |
| DFTX Definium Therapeutics, Inc. compare | −64.1% |
| ERAS Erasca, Inc. compare | −78.3% |
| COGT Cogent Biosciences, Inc. compare | −146.6% |
| TVTX Travere Therapeutics, Inc. compare | −252.8% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement